| Taiho Oncology, Inc. |
64842072709 |
INQOVI Tablets, 35 mg. 5's |
2020-08-31 |
7495.0000 |
The price is $7,495.00 per pack. Marketing plans will consist of print ads; journal ads, direct mail, and in-person calls to HCPs. |
None |
10000 |
None |
1 |
None |
None |
None |
None |
None |
None |
| TARO PHARMACEUTICALS |
51672530708 |
Dapsone Topical Gel 7.5% Pump 90GM |
2020-01-02 |
707.8500 |
This product (NDA Approval) is being marketed in the generic, multisource space. Dapsone 7.5% gel is considered to be an Authorized Generic (AG) . This product is priced in the market to reflect a discount off of the Reference Drug listed by the FDA. Sun representatives who are responsible for generic sales do not promote the promote to health care providers. |
None |
None |
None |
None |
None |
None |
None |
None |
Taro Pharmaceutical USA . is a licensee for this Authorized Generic. This product is being marketed in the generic space. The product is priced to reflect a discount off of the Reference Drug listed by the FDA.
The estimated average of patients per month is unknown to Taro.
The product was not acquired. |
None |
| Teva Parenteral Medicines, Inc. |
00703400401 |
ROMIDEPSIN RTU INJ 27.5 MG/5.5ML 5.5ML |
2020-04-14 |
8796.1500 |
None |
1 |
20000 |
None |
None |
None |
None |
None |
None |
Estimated average of up to 20,000 prescriptions per year, based on historic IQVIA data on sales of romidepsin vials. Acquisition questions not applicable (and acquisition fields therefore left blank); Teva developed the product. |
None |
| Teva Pharmaceuticals USA |
63459030343 |
HERZUMA® (trastuzumab-pkrb) 150 MG / 50 ML - 1 Vial |
2020-03-16 |
1402.5000 |
None |
1 |
135 |
None |
None |
2016-10-04 |
1.0000 |
None |
Teva acquired rights on October 4, 2016 from Celltrion to commercialize HERZUMA and another biosimilar product for $160M in up-front payments plus additional payments dependent on product sales. The acquisition price for the HERZUMA rights was incorporated into the broader deal's overall purchase price, and thus, there was no one particular price that Teva paid to acquire those rights. We were, nonetheless, required to enter a non-zero value in the "Acquisition Cost" field, and so we entered "1.00." |
Average of approximately 250 patients per month anticipated (in total, across both NDC's). |
None |
| Teva Pharmaceuticals USA |
63459030547 |
HERZUMA® (trastuzumab-pkrb) 420 MG / 10 ML - 1 Vial |
2020-03-16 |
3927.0000 |
None |
1 |
112 |
None |
None |
2016-10-04 |
1.0000 |
None |
Teva acquired rights on October 4, 2016 from Celltrion to commercialize HERZUMA and another biosimilar product for $160M in up-front payments plus additional payments dependent on product sales. The acquisition price for the HERZUMA rights was incorporated into the broader deal's overall purchase price, and thus, there was no one particular price that Teva paid to acquire those rights. We were, nonetheless, required to enter a non-zero value in the "Acquisition Cost" field, and so we entered "1.00." |
Average of approximately 250 patients per month anticipated (in total, across both NDC's). |
None |
| Teva Pharmaceuticals USA |
00093351656 |
DEFERASIROX 180MG TABLETS 30 (launched under ANDA 209223) |
2020-04-24 |
2189.0700 |
None |
1 |
6770 |
None |
None |
None |
None |
None |
None |
Average of approximately 6,770 prescriptions per year, based on historic IQVIA data. Acquisition questions not applicable (and acquisition fields therefore left blank); Teva developed the product. |
None |
| Teva Pharmaceuticals USA |
00591395550 |
VIGABATRIN 500MG POWDER FOR SOL 50 |
2020-05-14 |
1665.7400 |
None |
1 |
23450 |
None |
None |
None |
None |
None |
None |
Average of approximately 23,450 prescriptions per year, based on historic IQVIA data. Acquisition questions not applicable (and acquisition fields therefore left blank); Teva developed the product. |
None |
| Teva Pharmaceuticals USA |
00093776624 |
EVEROLIMUS TABLETS 2.5MG 28 (7X4) |
2020-06-10 |
6419.4300 |
None |
1 |
2950 |
None |
None |
None |
None |
None |
None |
Average of approximately 2,950 prescriptions per year, based on historic IQVIA data. Acquisition questions not applicable (and acquisition fields therefore left blank); Teva developed the product. |
None |
| Teva Pharmaceuticals USA |
00093776724 |
EVEROLIMUS TABLETS 5MG 28 (7X4) |
2020-06-10 |
6714.6200 |
None |
1 |
12550 |
None |
None |
None |
None |
None |
None |
Average of approximately 12,550 prescriptions per year, based on historic IQVIA data. Acquisition questions not applicable (and acquisition fields therefore left blank); Teva developed the product. |
None |
| Teva Pharmaceuticals USA |
00093776824 |
EVEROLIMUS TABLETS 7.5MG 28 (7X4) |
2020-06-10 |
6714.6200 |
None |
1 |
4850 |
None |
None |
None |
None |
None |
None |
Average of approximately 4,850 prescriptions per year, based on historic IQVIA data. Acquisition questions not applicable (and acquisition fields therefore left blank); Teva developed the product. |
None |
| Teva Pharmaceuticals USA |
00093313331 |
IMIQUIMOD CREAM 3.75 PUMP %/ MG 1 |
2020-07-29 |
1064.5800 |
None |
1 |
1650 |
None |
None |
2016-08-02 |
33430000000.0000 |
None |
This product (the "Product") is an authorized generic version of Zyclara® Cream. Actavis Mid Atlantic LLC (“Actavis”) had certain rights to sell the Product, and on August 2, 2016, Teva acquired those rights, along with Actavis itself, as part of a broader deal involving other assets. The acquisition price for those rights was incorporated into that broader deal’s overall purchase price and, thus, there was no one particular price that Teva paid to acquire those rights. We were, nonetheless, required to enter a non-zero value in the "Acquisition Price" field, and so we entered $33,430,000,000, which is the total amount that Teva paid (along with roughly 100 million shares of Teva stock) in connection with the broader deal referenced above. Once again, and to be clear, this total is not representative of the amount that Teva paid for the rights to the Product in particular. |
Estimated average of approximately 1,650 prescriptions per year, based on historic IQVIA data. |
None |
| Teva Pharmaceuticals USA |
00093537601 |
Clozapine ODT 150mg/100 count |
2020-07-30 |
1726.3200 |
None |
1 |
1800000 |
None |
None |
None |
None |
None |
None |
Estimated average of approximately 25,400 prescriptions per year (across these three particular NDCs), based on historic IQVIA data, although research suggests that as many as 1.8 million Americans have been diagnosed with schizophrenia and/or schizoaffective disorder, the primary indications for this product. Acquisition fields left blank; Teva developed this product. |
None |
| Teva Pharmaceuticals USA |
00093537701 |
Clozapine ODT 200mg/100 count |
2020-07-30 |
2301.7700 |
None |
1 |
1800000 |
None |
None |
None |
None |
None |
None |
Estimated average of approximately 25,400 prescriptions per year (across these three particular NDCs), based on historic IQVIA data, although research suggests that as many as 1.8 million Americans have been diagnosed with schizophrenia and/or schizoaffective disorder, the primary indications for this product. Acquisition fields left blank; Teva developed this product. |
None |
| Teva Pharmaceuticals USA |
00093537784 |
Clozapine ODT 200mg/48 count |
2020-07-30 |
1104.8300 |
None |
1 |
1800000 |
None |
None |
None |
None |
None |
None |
Estimated average of approximately 25,400 prescriptions per year (across these three particular NDCs), based on historic IQVIA data, although research suggests that as many as 1.8 million Americans have been diagnosed with schizophrenia and/or schizoaffective disorder, the primary indications for this product. Acquisition fields left blank; Teva developed this product. |
None |
| Teva Pharmaceuticals USA |
00591405094 |
SILDENAFIL CITRATE 10MG/ML PWD ORSU 1 |
2020-08-17 |
984.9700 |
None |
1 |
17000 |
None |
None |
None |
None |
None |
None |
Estimated average of approximately 16,800 prescriptions per year, based on historic IQVIA data. Research similarly suggests that as many as 17,000 Americans have been diagnosed with pulmonary arterial hypertension, the primary indication for this product. Acquisition fields left blank; Teva developed this product. |
None |
| Teva Pharmaceuticals USA |
00093375028 |
TOBRAMYCIN SOL 300/4 MG/ML 28 |
2020-09-15 |
2672.2100 |
None |
1 |
24000 |
None |
None |
None |
None |
None |
None |
Estimated average of approximately 9,200 prescriptions per year (across these two particular NDCs), based on historic IQVIA data, although research suggests that as many as 24,000 Americans have been diagnosed with cystic fibrosis with Pseudomonas aeruginosa, the primary indication for this product. Acquisition fields left blank; Teva developed this product. |
None |
| Teva Pharmaceuticals USA |
00093375063 |
TOBRAMYCIN SOL 300/4 MG/ML 56 |
2020-09-15 |
5344.4200 |
None |
1 |
24000 |
None |
None |
None |
None |
None |
None |
Estimated average of approximately 9,200 prescriptions per year (across these two particular NDCs), based on historic IQVIA data, although research suggests that as many as 24,000 Americans have been diagnosed with cystic fibrosis with Pseudomonas aeruginosa, the primary indication for this product. Acquisition fields left blank; Teva developed this product. |
None |
| Teva Pharmaceuticals USA |
00093921906 |
DIMETHYL FUMARATE DR CAPSULES 240MG 60 |
2020-09-28 |
943.4500 |
None |
1 |
728000 |
None |
None |
2020-08-25 |
None |
1 |
None |
Estimated average of approximately 430,000 prescriptions per year, based on historic IQVIA data, although research suggests that as many as 728,000 Americans have been diagnosed with multiple sclerosis.
The product is an authorized generic version of TECFIDERA®, manufactured by Biogen Swiss Manufacturing GmbH (“Biogen”). Teva sells the product as Biogen’s distributor in the US market, pursuant to an agreement between the parties dated August 25, 2020. The economic terms of that agreement, including any payments by Teva to acquire the rights to sell the product from Biogen, are confidential and non-public. |
None |
| Teva Pharmaceuticals USA |
00093523456 |
EFAVIRENZ/EMTRICITABINE/TENOFOVIR TAB 600MG/200MG/300MG 30 |
2020-09-30 |
2365.8200 |
None |
1 |
1100000 |
None |
None |
None |
None |
None |
None |
Estimated average of approximately 168,000 prescriptions per year, based on historic IQVIA data. Research suggests that as many 1.1 million Americans have been diagnosed with HIV. Acquisition fields left blank; Teva developed this product. |
None |
| Teva Pharmaceuticals USA |
00093760756 |
EMTRICITABINE/TENOFOVIR TAB 200/300MG 30 |
2020-09-30 |
1455.4000 |
None |
1 |
1100000 |
None |
None |
None |
None |
None |
None |
Estimated average of approximately 1.4 million prescriptions per year, based on historic IQVIA data. Research suggests that as many 1.1 million Americans have been diagnosed with HIV. Acquisition fields left blank; Teva developed this product. |
None |
| The PharmaNetwork LLC |
53097056860 |
Marinol 2.5 mg, 60 capsules in 1 bottle |
2020-04-01 |
694.4300 |
None |
1 |
804500 |
1 |
None |
None |
None |
None |
None |
Marinol is indicated for anorexia associated with weight loss in patients with AIDS and for nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. There are approximately 1.2 million people in the U.S. living with HIV and it is estimated that 20% to 34% of those patients will experince some degree of wasting or anorexia. There are approximately 650,000 people per year receiving chemotherapy treatments in the U.S. in outpatient settings and it is estimated that 45 to 61% of patients with cancer experience chemotherapy-induced nausea and vomiting. ThePharmaNetwork's estimated volume of patients who may be prescribed Marinol is not available in the public domain nor is the estimated number of patients for this drug known to ThePharmaNetwork. The estimated number of patients provided is a combination of 34% of 1.2 million HIV patients and 61% of 650,000 chemotherapy patients.
ThePharmaNetwork did not acquire this product. Patheon Softgels Inc. is the supplier of this product and Alkem Laboratories Ltd. is the parent company of ThePharmaNetwork. |
None |
| Tolmar Inc |
63646004012 |
Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Topical Suspension, 2x60g |
2020-06-01 |
1669.9200 |
None |
1 |
8000000 |
None |
None |
None |
None |
None |
None |
8,000,000 patients estimated based on the National Psoriasis Foundation.
While specific marketing and pricing plans are not available in the public domain, this is a generic drug that is not marketed. Tolmar has a long history of responsible pricing based on several factors including value provided to the patient and the healthcare system, unmet medical need, research and development sustainability, and the competitive environment. |
None |
| Tolmar Inc |
63646004060 |
Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Topical Suspension, 60g |
2020-06-01 |
834.9600 |
None |
1 |
8000000 |
None |
None |
None |
None |
None |
None |
8,000,000 patients estimated based on the National Psoriasis Foundation.
While specific marketing and pricing plans are not available in the public domain, this is a generic drug that is not marketed. Tolmar has a long history of responsible pricing based on several factors including value provided to the patient and the healthcare system, unmet medical need, research and development sustainability, and the competitive environment. |
None |
| Tolmar Pharmaceuticals, Inc. |
62935015350 |
Fensolvi (leuprolide acetate) |
2020-06-05 |
22578.0000 |
None |
1 |
13700 |
None |
None |
None |
None |
None |
None |
None |
None |